Research Progress of Protein Kinase Inhibitors in Rheumatoid Arthritis

LUO Xing-yan,TANG Mei,ZOU Qiang,LIN Zhi-hua
DOI: https://doi.org/10.3969/j.issn.1674-2257.2013.01.036
2013-01-01
Abstract:Rheumatoid arthritis(RA) is a high incidence of autoimmune diseases with a large prevalence of population.Biological agents currently dominate the market for disease-modifying for RA,which target the key cytokines.Biological agents are also faced with many shortcomings,such as the requirement of repeated injections,expensive,and sometimes are ineffective in the treatment of RA.Nowadays,new generations of DMARDs,the inhibitors of Janus kinase,spleen tyrosine kinase and p38 kinase,have been entered the clinical trials.The development of those protein kinase inhibitors will open a new approach for the treatment of RA.
What problem does this paper attempt to address?